We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Carolina Liquid Chemistries Promotes Family of Clinical Chemistry Analyzers

By LabMedica International staff writers
Posted on 31 Jul 2018
Image: The EasyRA high-speed benchtop analyzer (Photo courtesy of Carolina Liquid Chemistries).
Image: The EasyRA high-speed benchtop analyzer (Photo courtesy of Carolina Liquid Chemistries).
Carolina Liquid Chemistries (Greensboro, NC, USA) promoted its EasyRA high-speed benchtop analyzer, its family of clinical chemistry analyzers, CLC800, CLC1600, CLC6410, and extensive menu of reagents at the 70th annual AACC Scientific Meeting & Clinical Lab Expo held from July 31 – August 2. The company also introduced the Maglumi 2000 immunoassay analyzer at the event held in Chicago, USA.

Carolina Liquid Chemistries offers an extensive clinical chemistry reagent menu, ranging from general chemistries to urine drug screens and cardiovascular tests such as LpPLA2. The company markets a complete line of cost effective chemistry analyzers and service options for clinical laboratories of all sizes.

At AACC 2018, Carolina Liquid Chemistries highlighted the EasyRA, a high-speed benchtop clinical chemistry analyzer that accommodates the diverse needs of small to medium sized laboratories. Its all-in-one system allows laboratories to perform moderately complex urine drug screens and general chemistry tests on a single analyzer. With 300 tests per hour (480 with integrated ISE), an intuitive user interface, and the ability to analyze STAT samples in less than eight minutes, it is well suited for a variety of clinical laboratories located in satellite facilities, physician offices, pain management clinics, and urgent care centers.

In addition to the EasyRA, the company highlighted its family of floor model chemistry analyzers, the CLC800, CLC1600, and the CLC6410, which offer high throughputs from 400 to 900 to 3,200 photometric tests per hour. The FDA-cleared clinical chemistry analyzers are excellent for clinical laboratories located in mid-size group practices, large clinics, small and large hospitals or reference laboratories of all sizes.

Carolina Liquid Chemistries also highlighted its extensive reagent menu of products for both general chemistry and urine drug testing. This included 40 general chemistries, 27 urine drug screens, 15 immunochemistries and 24 special chemistries, including vLp-PLA2 (PLAC), Vitamin D (2-part), Procalcitonin (PCT) and Human Κ/λ Free Light Chain. Also on display at the event was the Maglumi 2000 immunoassay analyzer.

Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
Clinical Informatics Platform
CLARION™

Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers

Minimal residual disease testing is increasingly used to guide adjuvant therapy and surveillance in solid tumors, but detecting very low levels of circulating tumor DNA remains challenging in routine practice.... Read more

Microbiology

view channel
Image: Multidrug-resistant Klebsiella pneumoniae is a growing community health concern, causing recurrent UTIs in older adults and complicating first-line antibiotic treatment (Image Credit: Adobe Stock)

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Industry

view channel
Image: The proposed immunoassay uses ALZpath’s pTau217 antibody to detect Alzheimer’s disease biology in blood, supporting the growing role of blood-based biomarkers in clinical care (Photo courtesy of Shutterstock)

Agreement Supports pTau217-Based Alzheimer’s Blood Test Development

As disease-modifying therapies for Alzheimer’s disease expand, accessible diagnostics are increasingly needed to identify patients earlier. Current confirmatory methods, including PET imaging and cerebrospinal... Read more
ADLM